Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.66 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.61 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | PAK4 | O96013 | 7/20 | 0.53 |
| ▸ | ULK1 | O75385 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13154698 | 0.92 | RET (0.66) | RETABCG2SLC2A1KDRPAK4 | |
| SCHEMBL3579006 | 0.92 | RET (0.66) | RETABCG2SLC2A1KDRPAK4 | |
| SCHEMBL3100763 | 0.91 | RET (0.63) | RETABCG2SLC2A1KDRPAK4 | |
| SCHEMBL13154700 | 0.91 | RET (0.65) | RETABCG2SLC2A1KDRPAK4 | |
| SCHEMBL3588957 | 0.90 | ABCG2 (0.76) | RETABCG2SLC2A1KDRPAK4 | |
| SCHEMBL3586555 | 0.89 | RET (0.65) | RETABCG2SLC2A1KDRPAK4 | |
| SCHEMBL13154704 | 0.89 | RET (0.70) | RETABCG2SLC2A1KDRPAK4 | |
| SCHEMBL3577677 | 0.88 | ABCG2 (0.63) | RETABCG2SLC2A1KDRPAK4 | |
| SCHEMBL3578638 | 0.88 | RET (0.64) | RETABCG2SLC2A1KDRPAK4 | |
| SCHEMBL3578899 | 0.86 | RET (0.62) | RETABCG2SLC2A1KDRPAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137324-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPHALAN | 2010-06-03 | — | — | US | disclosed |
| US-20100125139-A1 | PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF | BANKSTON DONALD | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137324-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | RET 801/4885ABCG2 3107/4885SLC2A1 4666/4885 |
| US-20100125139-A1 | PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF | ROCK1, ROCK2, CIT | RET 1193/4885ABCG2 1652/4885SLC2A1 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.